Clinical trials: Cancer of Skin
HR+ Metastatic Breast Cancer, Breast Cancer
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
This trial is being conducted to investigate the safety, tolerability, pharmacokinetics (the effect the body has on the drug), and pharmacodynamics (the effect the drug has on the body) of GMI-1359 when given with…
- Conditions
- HR+ Metastatic Breast Cancer, Breast Cancer, Breast Cancer Metastatic
- Trial name
- NCT04197999
- Testing
- GMI-1359
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- GlycoMimetics Incorporated
Melanoma
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
This is a phase 2, single arm, open label, adaptive design study to determine the preliminary anti-tumor activity and confirm the safety of IT BO-112 in combination with intravenous (IV) pembrolizumab.
- Trial name
- SPOTLIGHT203 (NCT04570332)
- Testing
- BO-112 plus pembrolizumab, Tissue Biopsies
- Where
- 19 sites in France, Spain
- Volunteers
- 42 people
- Sponsor
- Highlight Therapeutics
Estrogen Receptor-Positive, HER2-Negative
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)
For patients with ER-positive, HER2-negative breast cancer, blockage of the ER pathway has been proven to be an effective anticancer approach. These patients showed good response to endocrine therapy.
- Conditions
- Estrogen Receptor-Positive, HER2-Negative, Locally Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- ENZENO (NCT04669587)
- Testing
- ZB716, Palbociclib
- Where
- 8 sites in United States, South Korea
- Volunteers
- 106 people
- Sponsor
- EnhancedBio USA Inc.
Advanced, Metastatic Breast Cancer
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer
The primary purpose of this study was to assess the efficacy of ribociclib, as measured by progression free survival (PFS), in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2…
- Trial name
- MONALEESA-2 (NCT01958021)
- Testing
- Ribociclib, Letrozole
- Where
- 221 sites in United States, Argentina and 27 more
- Volunteers
- 668 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Barriers to Therapeutic Exercise in Breast Cancer Patients Before, During, and After Chemotherapy
Cancer is one of the leading causes of mortality. First-choice cancer treatments, such as chemotherapy, have increased the survival of people with cancer, although they are not without adverse effects such as cardiotoxicity…
- Trial name
- NCT06828614
- Testing
- Chemotherapy
- Where
- Spain
- Volunteers
- 111 people
- Sponsor
- University of Valencia
Breast Cancer
The Use of 3D Surface Imaging in the Objective Assessment of Breast Conserving Therapy
3D surface imaging has been used in the objective evaluation of cosmetic outcome of oncoplastic procedures such as breast reconstruction and lipofilling, however there is only one article published relating to Breast Conserving…
- Trial name
- 3DBCT (NCT02304614)
- Testing
- 3D surface imaging using a non portable and portable camera, Patient reported outcome measure (PROM): BREAST-Q, 2D photography
- Where
- United Kingdom
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
This study was a Phase 1 and pharmacologic open-labeled dose-escalation trial of MM-121 in combination with paclitaxel using a "3+3" design.
- Conditions
- Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
- Trial name
- NCT01209195
- Testing
- MM-121, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Merrimack Pharmaceuticals
Breast Cancer
A Pilot Study Evaluating the Immunologic Status of Patients With HER2+ Breast Cancer
This is a pilot study to gather preliminary data on the baseline immunologic status of patients with HER-2(+) breast cancer and to establish an immune monitoring laboratory for future clinical trial.
- Trial name
- NCT00477139
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Breast Neoplasms
The Significance of Radiologically Detected Intramammary Lymph Nodes in Prediction of Axillary Lymph Nodes Status in Breast Cancer Patients
Breast cancer is a major cause of mortality among women if not treated in early stages. Early screening and diagnosis have a lot to do with the therapeutic effect of prognosis .
- Trial name
- NCT05214781
- Testing
- modified radical mastectomy
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Melanoma
High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph Nodes
The study is designed to see if a high-resolution MRI scan of lymph node areas near where a melanoma has been removed from the skin can pick up the spread of melanoma to those lymph nodes with a high degree of accuracy.
- Trial name
- NCT00463892
- Testing
- High-resolution contrast-enhanced MRI scan
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Redwood Regional Medical Group
Malignant Neoplasm of Breast TNM Staging Distant Metastasis (M), Untreated Bone Metastases
NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer
This study will look at two new technologies being developed for measuring cancer in bones. One of these technologies is a substance called Sodium Fluoride (NaF). Fluoride is a normal body substance.
- Trial name
- NCT02103634
- Testing
- NaF PET/MRI, NaF PET/CT, FDG PET/CT
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Case Comprehensive Cancer Center
Lung Cancer, Melanoma
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
This is a Phase I, open-label, multi-centre, drug combination study of double and triple combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral selumetinib plus IV MEDI4736 and IV tremelimumab…
- Conditions
- Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer
- Trial name
- NCT02586987
- Testing
- Selumetinib, MEDI4736, Tremelimumab
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
Body Mass Index 25 or Greater, BRCA1 Gene Mutation
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
This pilot clinical trial studies different types of energy balance interventions to see how well they work in increasing the physical activity levels of breast cancer gene-positive patients, Lynch syndrome-positive patients…
- Conditions
- Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Carcinoma
- Trial name
- NCT02194387
- Testing
- Dietary Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Laser Therapy for the Prevention of Radiodermatitis in Breast Cancer Patients
Up to 90% of the radiotherapy patients will develop a certain degree of skin reaction at the treated area, also known as radiodermatitis (RD).
- Trial name
- TRANSDERMIS (NCT02443493)
- Testing
- Low-level laser, radiotherapy
- Where
- Belgium
- Volunteers
- 139 people
- Sponsor
- Hasselt University
Advanced Melanoma, Metastatic Melanoma
Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma
This is a multi-center, open-label, phase 2 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with locally advanced or metastatic melanoma who have failed in routine systemic treatment.
- Trial name
- NCT03013101
- Testing
- humanized anti-PD-1 monoclonal antibody toripalimab
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Psoriasis
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
This will be a single-center, open-label clinical study to determine the efficacy and safety of secukinumab in the treatment of moderate to severe psoriasis vulgaris in skin of color (SOC) (FST IV-VI).
- Trial name
- NCT04571567
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Saakshi Khattri
Locally Recurrent and Metastatic Breast Cancer
Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer
This open-label, dose-finding, multi-center study is designed to determine the safety and the maximum tolerated dose of AMG 706 given once daily in combination with either weekly paclitaxel (Arm A) or once-every-3 week docetaxel…
- Trial name
- NCT00322400
- Testing
- Docetaxel, Paclitaxel, AMG 706
- Volunteers
- 46 people
- Sponsor
- Amgen
Breast Cancer
Effect of Early vs Late Drainage Removal in Women After Radical Mastectomy With Axillary Clearance
The aim of the study is to assess whether early drainage removal in patients with less than 150ml of lymph in postoperative day 1 can reduce total lymphorrhoea
- Trial name
- CHLONKA (NCT01221064)
- Testing
- Early drainage removal, Late drainage removal
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
Advanced Cancer, Lung Cancer
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
This is a multicenter, open-label, phase I/II basket study, evaluating the safety, tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448 (also known as GSK4428859A or belrestotug) combined with…
- Conditions
- Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- TIG-006 (NCT05060432)
- Testing
- EOS-448, pembrolizumab, inupadenant
- Where
- 42 sites in United States, Belgium and 4 more
- Volunteers
- 153 people
- Sponsor
- iTeos Belgium SA
Head and Neck Cancer, Lymphedema of Face
Two Different Physiotherapy Programs in Lymphedema Following Head and Neck Cancer Treatment
The aim of this study was to determine the effects of complex decongestive physiotherapy (CDP) and home programs on internal/external lymphedema, staging, fibrosis, and three-dimensional (3D) surface scanning and volume…
- Conditions
- Head and Neck Cancer, Lymphedema of Face, Fibrosis; Skin
- Trial name
- NCT04286698
- Testing
- Complex decongestive physiotherapy, Home program
- Where
- Turkey (Türkiye)
- Volunteers
- 21 people
- Sponsor
- Izmir Bakircay University